There are three IPOs scheduled to debut on the markets this week. While the total dollar amount is relatively small to what investors may have grown accustomed to recently, the types of companies going public could offer promising trends.
Full IPO calendar & reports HERE
The following IPOs are slated for the week of April 20, ranked by IPO size:
(1) Based in Greenwood Village, CO, National Storage Affiliates Trust (NSA) scheduled a $320 million IPO on the NYSE with a market capitalization of $674 million, at a price range midpoint of $16 for Thursday, April 23, 2015.
NSA is a Maryland real estate investment trust focused on the ownership, operation, and acquisition of self-storage properties located within the top 100 MSAs throughout the United States.
According to the 2014 Self-Storage Almanac, NSA is the sixth largest owner and operator of self-storage properties and the largest privately-owned operator of self-storage properties in the United States based on number of properties, self-storage units, and rentable square footage.
(2) Based in San Jose, CA, Apigee (APIC) scheduled an $87 million IPO on Nasdaq with a market capitalization of $495 million, at a price range midpoint of $17 for Friday, April 24, 2015.
APIC provides an innovative software platform that allows businesses to design, deploy, and scale APIs as a connection layer between their core IT systems and data and the applications with which their customers, partners, employees and other users engage with their business.
(3) Based in San Diego, CA, Viking Therapeutics (VKTX) scheduled a $20 million IPO on the Nasdaq with a market capitalization of $69 million, at a price range midpoint of $8 for Friday, April 24, 2015.
VKTX is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.
VKTX has exclusive worldwide rights to a portfolio of five drug candidates in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated (LGND). LGND has a market cap of $1.7 billion.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer